ERES – Page 10 – Pharma.Tips

Traceability breaks in supply chain during regulatory inspection – preventing repeat serialization deviations

Mitigating Supply Chain Traceability Disruptions During Regulatory Inspections In the highly regulated pharmaceutical industry, maintaining robust traceability in the supply chain is paramount. However, traceability breaks can occur during the…

Traceability breaks in supply chain during distribution – recall readiness impact

Addressing Traceability Breaks in Distribution and Their Impact on Recall Readiness In the pharmaceutical industry, maintaining effective traceability throughout the supply chain is crucial for ensuring product integrity and compliance…

Aggregation failures during distribution – inspection questioning scenarios

Addressing Aggregation Failures During Distribution: A Comprehensive Playbook In the pharmaceutical industry, aggregation failures during distribution can lead to significant compliance risks and operational inefficiencies. Such failures not only jeopardize…

System access controls weak during inspection walkthrough – 21 CFR Part 11 compliance gaps

Addressing Weak System Access Controls During Inspections to Ensure 21 CFR Part 11 Compliance Pharmaceutical manufacturing facilities are under constant scrutiny to maintain compliance with regulations governing electronic records and…

Electronic signatures misused during compliance audit – CAPA and revalidation strategy

Addressing Misuse of Electronic Signatures in Compliance Audits: A Comprehensive Playbook In today’s highly regulated pharmaceutical landscape, the efficacy of electronic signatures during compliance audits is critical. Misuse of electronic…

Record retention failures during system operation – CAPA and revalidation strategy

Managing Record Retention Failures During Operational Systems: A Strategic Playbook Failures in record retention during system operations can disrupt processes, hinder compliance, and potentially lead to regulatory sanctions. For pharmaceutical…

Record retention failures during system upgrade – inspection evidence requirements

Addressing Record Retention Failures During System Upgrades: An Inspection-Ready Playbook In the pharmaceutical industry, system upgrades are a critical part of maintaining compliance and operational efficiency. However, these transitions can…

Electronic signatures misused during compliance audit – risk-based ERES remediation

Addressing the Misuse of Electronic Signatures During Compliance Audits: A Practical Playbook In the dynamic landscape of pharmaceutical manufacturing and quality compliance, the misuse of electronic signatures during audits poses…

Record retention failures during system upgrade – preventing repeat Part 11 findings

Addressing Record Retention Failures During System Upgrades to Prevent Part 11 Findings In the ever-evolving landscape of pharmaceutical manufacturing, system upgrades can inadvertently lead to record retention failures, posing significant…

Record retention failures during validation lifecycle – preventing repeat Part 11 findings

Addressing Record Retention Issues During the Validation Lifecycle to Prevent Part 11 Findings Record retention failures represent a critical threat in pharmaceutical manufacturing, particularly during the validation lifecycle of Electronic…

Hybrid paper-electronic workflows uncontrolled during compliance audit – CAPA and revalidation strategy

Strategies for Managing Uncontrolled Hybrid Paper-Electronic Workflows During Compliance Audits In the evolving landscape of pharmaceutical manufacturing, the integration of hybrid paper-electronic workflows has become a common practice. While these…

Electronic signatures misused during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Electronic Signature Misuse Throughout the Validation Lifecycle In pharmaceutical manufacturing and quality control, the implementation of electronic signatures holds significant potential for operational efficiency and compliance. However, misuse of…